

Quantifying Intangibles: Operating Model Assumptions In Biotech Valuation

Na Kyung Kim

University of Chicago (Chicago, IL, USA)

Abstract

Valuing biotechnology companies presents distinct challenges due to their reliance on intangible assets, such as intellectual property, early-stage research pipelines, regulatory milestones, and specialized human capital. Unlike firms in traditional sectors with steady cash flows and tangible assets, biotech companies often operate in pre-revenue or early-revenue stages, making valuation highly sensitive to subjective model assumptions. These include probabilities of success for drug development, time-to-market forecasts, cost of capital, and expectations around licensing and commercialization revenues.

This review examines how such assumptions are incorporated into biotech valuation frameworks, focusing on methods like discounted cash flow (DCF), risk-adjusted net present value (rNPV), and real options analysis. It evaluates the influence of variables such as R&D expenditure, clinical trial outcomes, regulatory pathways, and go-to-market strategies on model accuracy and investment decision-making. The paper also explores how practitioners quantify intangible drivers, ranging from patents and platform technologies to early-stage data and scientific expertise, within valuation models. It assesses the role of strategic alliances, licensing agreements, and M&A transactions as market-based indicators of underlying asset value. Techniques such as Monte Carlo simulations, probability-weighted forecasting, and external benchmarking are discussed as tools to better manage uncertainty and refine model robustness. In addition, the review addresses accounting and regulatory considerations, sector-specific risks, and the limitations of traditional financial reporting in capturing biotech value. It highlights emerging applications of machine learning and data analytics for predicting clinical and financial outcomes. The paper concludes by identifying research gaps and offering recommendations for improving transparency, standardizing assumptions, and integrating qualitative judgment with quantitative rigor. This review provides analysts, investors, and life science professionals with a structured perspective on designing valuation models that meaningfully account for the intangible and uncertain nature of biotech enterprises.

Keywords: Biotech Valuation, Intangible Assets, Operating Model Assumptions, Risk-Adjusted NPV (rNPV), Real Options Analysis.

I. INTRODUCTION

The valuation of biotechnology companies is widely regarded as one of the most challenging problems in modern financial analysis, given that business value is tied less to observable revenues or physical infrastructure than to unobservable science, regulatory outcomes, and development prospects. Unlike traditional industrial sectors, which benefit from tangible asset bases and relatively predictable demand patterns as credible anchors for valuation, many biotechnology companies operate for extended periods in pre-revenue, early-revenue, or single-asset development stages, rendering backward-looking financial metrics largely inadequate. This has made valuation highly sensitive to forward-looking expectations regarding probability of clinical success, the timing of regulatory approval, and the pricing, reimbursement, and long-term competitiveness of therapeutics. The translation of these expectations into systematic valuation frameworks, most notably discounted cash flow (DCF), risk-adjusted net present value (rNPV), and real options analysis, enables scientific and regulatory uncertainty to be expressed as probabilistic financial projections. However, these frameworks are also highly susceptible to minor assumption changes that can produce severe model risk, wide valuation dispersions, and significant subjectivity across analysts

and institutions, further complicating capital allocation and investment comparability [1], [2]. As investment in life-science innovation increasingly focuses on early-stage discovery, platform technologies, and precision medicine, improving the rigor, transparency, and empirical grounding of valuation methods has become a shared priority across academia, industry, and policy [3], [4].

It is against this backdrop that this paper examines operating model assumptions as the primary mechanism through which intangible scientific innovation is translated into quantifiable financial value in biotechnology firms. The review is interdisciplinary, drawing on corporate finance, accounting theory, pharmaceutical economics, regulatory science, and innovation management, and discusses the effects of R&D productivity, intellectual property strength, strategic collaboration structures, and regulatory pathways on cash flow projections, risk adjustment, and discounting behavior. Particular attention is paid to probabilistic models, scenario-based forecasting, and emerging data-driven analytical methods expected to improve the quality of clinical and commercial outcome estimates under conditions of limited information. The paper seeks to explain both what modern biotech valuation does well and where it falls short, through a series of methodological assessments that identify patterns and structural deficiencies in actual implementation by investors, analysts, and life-science firms. Ultimately, it is hoped that the paper will contribute to the development of more consistent, evidence-based, and decision-relevant valuation frameworks capable of capturing the economically transformative yet deeply uncertain nature of biomedical innovation, and its role in the future of healthcare and investment [3], [4].

1.1 Background and Motivation

The biotechnology sector is defined by knowledge-intensive research, long development cycles, regulatory dependence, and binary clinical outcomes, all of which make standard valuation logic difficult to apply. A substantial portion of firm value may reside in patents, proprietary data, early clinical results, and specialized human capital, none of which are well represented in conventional financial statements. Traditional accounting paradigms focus on reported transactions and tangible assets, systematically undervaluing innovation-driven businesses and widening the gap between book and market capitalization [5]. Investors and analysts therefore turn to forward-looking operating models that simulate drug development pathways, commercialization scenarios, and lifecycle revenues. The fundamental components of these models include probability-weighted cash flow forecasting, stage-sensitive discount rates, and scenario-based sensitivity analysis grounded in pharmaceutical industry benchmarks. One such technique, rNPV, extends classical DCF by directly modeling clinical transition probabilities and regulatory risk, while real options theory captures managerial flexibility to expand, delay, license, or abandon development programs in the face of uncertainty [6], [7]. These theoretical tools form the foundation of modern biotech valuation and motivate the need for systematic analysis.

Biotech valuation integrates principles of corporate finance, decision theory, and health economics at a fundamental level. Cash flow expectations are shaped by epidemiology, pricing controls, reimbursement systems, and competitive therapeutics, while discount rates reflect technological risk, capital structure, and macroeconomic conditions. This convergence of disciplines creates a valuation environment in which scientific evolution and financial modeling are inseparable, underscoring the importance of systematic assumptions and transparent processes [8].

1.2 Challenges in Biotech Valuation

Valuing biotechnology firms involves multidimensional challenges arising from extreme uncertainty, limited historical data, and nonlinear development risk. Drug discovery and clinical testing proceed through successive phases, and probabilities of success decline sharply at each stage, meaning that early-stage assets can carry significant theoretical value alongside a high probability of failure. Even small changes in assumptions regarding clinical efficacy, approval timing, market size, or pricing can produce disproportionately large shifts in valuation, reducing comparability across analysts and exposing the process to behavioral bias [2], [9]. Moreover, regulatory outcomes are shaped by evolving scientific standards and policy environments, making time-to-market forecasting inherently unstable. Partnering arrangements, milestone payments, royalty agreements, and future financing dilution must also be incorporated into financial projections, adding further layers of conditional uncertainty.

A second fundamental challenge is the difficulty of measuring scientific quality as an intangible. Patent breadth, platform scale, biomarker validation, and the expertise of the research team all significantly influence the probability of success, yet cannot be captured numerically with precision. Market signals, such as licensing deals and acquisitions, are partial proxies, but deal pricing itself reflects strategic considerations that may not correspond to intrinsic asset value. Traditional accounting disclosures do not convey this informational richness, necessitating reliance on qualitative judgment and probabilistic modeling. Even sophisticated simulation methods such as Monte Carlo analysis are constrained by the subjectivity of inputs and limited empirical calibration. Biotech valuation is therefore as much a matter of structured inference as deterministic finance, demanding methodological refinement and cross-disciplinary integration of evidence [1], [10].

1.3 Scope and Objectives of the Review

This review examines how operating model assumptions shape the quantified value of biotechnology enterprises within DCF, rNPV, and real options frameworks. It synthesizes scholarly literature and industry practice to assess how technical and regulatory probability of success, development timelines, commercialization plans, and cost structures are incorporated into financial estimation. The paper also examines methods for converting intangible drivers, including intellectual property strength, platform technologies, and strategic collaborations, into quantifiable valuation inputs. Beyond methodological comparison, the paper identifies sources of bias, uncertainty, and inconsistency in existing valuation approaches, and evaluates emerging solutions such as probabilistic simulation, external benchmarking, and machine-learning-assisted forecasting. By clarifying conceptual assumptions and identifying research gaps, this review aims to support more transparent, standardized, and decision-relevant valuation practices for investors, analysts, and life-science practitioners navigating the uncertainty inherent in biotech innovation [3], [6].

II. UNDERSTANDING INTANGIBLES IN BIOTECHNOLOGY

Non-physical, knowledge-based resources constitute a large share of the economic value of biotechnology enterprises and are the primary determinants of innovation potential, regulatory success, and future commercialization. Unlike asset-intensive sectors, where valuation relies on physical infrastructure or expected tangible income streams, biotech companies operate under conditions of scientific uncertainty, and the most financially relevant aspects of their business depend heavily on intangible factors. These include proprietary intellectual property, experimental data, platform technologies, scientific know-how, and collaborative ecosystems, all of which influence the probability and scalability of therapeutic success. The fact that these assets are largely absent from

balance sheets at fair economic value means that analysts must reconstruct their worth through probabilistic forecasting, comparable transaction benchmarking, and scenario modeling. This is not merely a measurement problem; it requires translating qualitative scientific progress into quantitative financial expectations shaped by regulatory pathways, competitive dynamics, and reimbursement contexts. Moreover, because drug development follows a lifecycle, encompassing discovery, preclinical validation, clinical trials, approval, and commercialization, intangible value is not a fixed stock but rather something that evolves at each stage. Accordingly, stage-based probabilities, option-like decision flexibility, and external market indicators are increasingly integrated into valuation models in the pursuit of capturing the economic value of innovation. It is this interplay of intangibles that lies at the core of sound biotech operating model design and drives the explanation of investment risk in life-science portfolios [11], [12].

2.1 Defining Intangible Assets in Biotech

Intangible resources in the biotechnology context encompass the knowledge, scientific expertise, and development momentum that, in combination, enable therapeutic innovation. Intellectual property rights, most notably patents on molecular entities, biologic constructs, manufacturing processes, and platform technologies, provide temporary exclusivity and pricing power as the legal basis for value protection. Beyond formal IP, firms accumulate proprietary data, preclinical findings, biomarker evidence, and clinical results that confer competitive advantage but are difficult to quantify using standard accounting methods. These resources are further supplemented by human capital, in which the tacit knowledge of scientists, clinicians, and regulatory experts collectively shapes program design and the likelihood of successful approval. Because accounting standards require research and development to be expensed rather than capitalized, reported earnings frequently diverge from underlying economic value, compelling analysts to construct forward-looking benefit streams as proxies for future cash flows [13].

Beyond legal and technical considerations, biotech intangibles also encompass organizational learning, platform scalability, and ecosystem connectivity. Gene editing, mRNA delivery, and antibody engineering technologies function like options in that they can be applied to a broad range of downstream therapeutic applications. Similarly, accumulated regulatory relationships and clinical execution capabilities, what might be called intangible infrastructure, reduce uncertainty across future programs. These layered knowledge assets are cumulative and emergent, and cannot be adequately measured through conventional valuation ratios. Sound biotech valuation therefore requires integrating qualitative scientific assessment with quantitative probability modeling, treating intangible drivers as direct inputs into projected cash flows, discount rates, and strategic scenario planning, rather than as residual or speculative value elements [11], [14].

2.2 Key Value Drivers: IP, R&D Pipeline, and Human Capital

The primary sources of intangible value in biotechnology cluster around three interdependent pillars: intellectual property strength, R&D pipeline quality, and specialized human capital. Strong patent portfolios extend exclusivity periods and deter competitors, thereby determining the duration of revenue protection and pricing flexibility. The R&D pipeline captures scientific novelty and the probabilistic nature of the development process across clinical stages, directly influencing anticipated cash flows and risk-adjusted valuation. Meanwhile, strong leadership and established research relationships enhance execution quality, partnership credibility, and the speed of decision-making under uncertainty. The combination of these drivers transforms original

scientific discovery into a commercially scalable business opportunity and constitutes the primary input into rNPV and real-options-based valuation logic [12], [15].

Table 1. Core Intangible Value Drivers in Biotechnology

Driver	Description	Valuation Relevance	Measurement Proxies	Risk Factors
Intellectual Property	Patents, exclusivity rights, proprietary platforms	Determines the duration of competitive advantage and pricing power	Patent life, breadth, citation strength, freedom-to-operate	Litigation, patent expiry, technological substitution
R&D Pipeline	Portfolio of candidates across clinical stages	Drives probability-weighted future revenues	Phase distribution, probability of success, target market size	Clinical failure, delays, and regulatory rejection
Human Capital	Scientific leadership, technical expertise, execution capability	Influences development efficiency and strategic credibility	Team track record, publications, prior approvals	Talent attrition, execution misalignment

2.3 The Role of Strategic Partnerships and Licensing

Strategic alliances, co-development agreements, and licensing deals serve as market-tested indicators of intangible value in biotechnology ecosystems. Because external partners, often large pharmaceutical companies, conduct rigorous scientific and commercial due diligence before committing capital, upfront payments, milestone structures, and royalty rates implicitly reveal expectations regarding technical success and market potential. These alliances also diversify development risk, provide access to regulatory expertise, and accelerate commercialization through established distribution channels. Partnership economics are incorporated directly into valuation cash flow forecasts on a probability-weighted basis and simultaneously provide observable reference points. Merger and acquisition premiums and licensing activity therefore strengthen internal modeling by grounding assumptions in actual transaction data, improving robustness and supporting investor confidence [13], [15].

Table 2. Strategic Transactions as Indicators of Intangible Value

Transaction Type	Structure	Valuation Insight	Financial Components	Key Limitations
Licensing Agreement	Rights granted for development/commercialization	External validation of scientific and market potential	Upfront fees, milestones, royalties	Deal-specific negotiation effects
Co-Development Partnership	Shared R&D cost and commercialization	Risk sharing and capability complementarity	Cost sharing, profit split	Governance complexity
Acquisition / M&A	Full ownership transfer	Market-based pricing of pipeline and platform	Acquisition premium, earn-outs	Strategic synergies may distort intrinsic value

III. OVERVIEW OF BIOTECH VALUATION METHODOLOGIES

Biotech valuation relies on forward-looking, uncertainty-sensitive financial models that translate scientific development and regulatory risk into economic value. Because most biotech firms lack historical revenue track records, analysts must rely on probabilistic projections, scenario-based models, and option-logic valuation rather than traditional ratio-based approaches. The most widely used methodologies, discounted cash flow (DCF), risk-adjusted net present value (rNPV), and real options analysis, attempt to incorporate development timelines, commercialization expectations, and cost of capital into organized financial forecasts. Each approach also reflects a distinct philosophical stance on uncertainty: DCF places greater emphasis on deterministic forecasts, rNPV incorporates probability-weighted cash flows, and real options treats drug development as a series of managerial decisions made as information unfolds over time. In practice, valuation professionals are increasingly likely to integrate these methods with benchmarking from licensing transactions and pipeline acquisitions to improve realism and reduce model bias. Understanding the conceptual foundations, strengths, and limitations of each methodology is therefore essential both for constructing sound biotech operating models and for assessing the risks of investing in innovation-based healthcare markets.

Most valuations are anchored on the conceptual foundation of discounted cash flow analysis, which projects future cash flows from approved or late-stage assets and discounts them to present value at a risk-adjusted cost of capital. However, the deterministic nature of DCF is poorly suited to accommodating binary clinical events, staged investment decisions, and evolving probabilities across drug development phases. To address these shortcomings, practitioners are increasingly turning to rNPV, which multiplies future cash flows by stage-dependent probabilities of success and applies discount rates calibrated to reflect both technical and regulatory risk. Building on this,

real options analysis models the strategic capability to delay, expand, license, or terminate development programs as uncertainty resolves over time. These approaches are collectively regarded as the analytical core of biotech valuation methodology, though each carries its own assumptions that can significantly influence the resulting enterprise value estimate.

Table 3. Core Valuation Methods in Biotechnology and Key Limitations

Methodology	Conceptual Basis	Key Strengths	Primary Limitations	Typical Use Case
Discounted Cash Flow (DCF)	Projects future free cash flows and discounts to present value using the cost of capital	Widely understood, transparent financial structure, useful for commercial-stage assets	Weak handling of binary risk, deterministic assumptions, sensitive to terminal value and discount rate	Late-stage or revenue-generating biotech firms
Risk-Adjusted Net Present Value (rNPV)	Probability-weights cash flows by clinical and regulatory success rates	Better representation of staged uncertainty, aligned with the drug development process	Depends heavily on assumed probabilities and timelines, still largely static	Clinical-stage pipeline valuation
Real Options Analysis	Values managerial flexibility under uncertainty using option-pricing logic	Captures staged investment, learning effects, and strategic decision points	Complex modeling, parameter estimation difficulty, and limited practical adoption	Early-stage innovation and platform technologies

Considered comparatively, these methodologies reflect different tradeoffs in how valuation uncertainty is handled. DCF offers transparency but amplifies certainty through its deterministic structure; rNPV provides probabilistic realism but is heavily assumption-dependent; and real options analysis captures strategic flexibility at the cost of increased modeling complexity. As a result, current best practice tends to integrate multiple models and evidence-based approaches, triangulating value across methods and reducing dependence on any single modeling framework.


Table 4. Comparative Overview of Biotech Valuation Methodologies

Dimension	DCF	rNPV	Real Options
Treatment of Uncertainty	Implicit in the discount rate	Explicit probability weighting	Modeled as staged optionality
Alignment with Drug Development	Limited	Strong	Very strong
Data Requirements	Financial forecasts	Clinical probabilities + financials	Volatility, timing, decision paths
Analytical Complexity	Low-moderate	Moderate	High
Practical Industry Use	High for late stage	Very common	Selective/specialized
Sensitivity to Assumptions	High	Very high	High but scenario-flexible

IV. CRITICAL OPERATING MODEL ASSUMPTIONS

In biotechnology, valuation outcomes are fundamentally determined by a set of interrelated operating model assumptions that transform uncertain scientific advances into projected financial activities. Unlike mature industries where historical revenues anchor future predictions, biotech valuation is driven by forward-looking expectations regarding clinical success, regulatory approval, commercialization timing, capital intensity, and long-term profitability. Even minor changes in these assumptions can produce disproportionately large valuation shifts, reflecting the nonlinear and binary nature of drug development. Analysts must therefore combine probabilistic reasoning, staged investment logic, and scenario-based forecasting to ensure that projected cash flows are economically credible [16]. The principal drivers include the probability of technical and regulatory success (PTRS) at each development phase, anticipated time-to-market and product lifecycle, R&D spending trajectories and partnership economics, and the cost of capital applied to discount uncertain future returns [17]. These variables are mutually dependent: an extended development timeline amplifies capital requirements and discounting pressure, while higher clinical probabilities may justify reduced risk premiums. Given the scarcity of empirical data and the path-dependent nature of outcomes, operating assumptions typically draw on industry benchmarks, historical transition data, and expert scientific judgment [18]. Assumption design and sensitivity testing must therefore be conducted transparently to support credible valuation. Understanding the influence of these underlying parameters on enterprise value is essential to enhancing comparability across analysts, building investor confidence, and aligning financial modeling with the actual economics of biomedical innovation [19].

Figure 1. Conceptual Structure of Critical Operating Model Assumptions in Biotech Valuation



4.1 Probability of Technical and Regulatory Success (PTRS)

PTRS refers to the likelihood of a therapeutic candidate advancing through clinical development and receiving regulatory approval, and it is one of the most critical parameters in biotech valuation. Given the sequential nature of clinical drug development and the historically declining transition probabilities across phases, valuation models must apply stage-specific success rates to revenue and cost estimates. These probabilities are typically derived from industry-wide statistical analyses, therapeutic-area benchmarks, and adjustments for the novelty of the mechanism or the strength of biomarker validation. Even minor modifications to PTRS assumptions can produce dramatic shifts in risk-adjusted net present value, particularly for early-stage assets where leverage is high. Furthermore, PTRS is not determined by science alone; regulatory precedents, trial design, safety signals, and competitive dynamics all influence approval probabilities. Analysts therefore synthesize quantitative transition data with qualitative clinical judgment to refine their estimates. Scenario modeling and sensitivity analysis are essential to assess downside risk and avoid over-reliance on optimistic assumptions. The validity of probability-weighted valuation models ultimately depends on the rigor of PTRS estimation.

4.2 Time-to-Market and Development Timelines

Development timelines determine the duration of capital at risk and have a direct influence on both discounting intensity and cumulative investment requirements. Biotech products may require years of preclinical research, multiphase clinical trials, and regulatory review, resulting in timelines that frequently exceed ten years. Any delay, whether due to enrollment challenges, safety concerns, manufacturing readiness, or regulatory feedback, can significantly erode present value. Conversely, breakthrough designations or expedited approval pathways can compress timelines and enhance valuation. Phase-level duration estimates, launch timing assumptions, and lifecycle revenue horizons must all be modeled carefully. Time-to-market also shapes competitive dynamics, as first-mover advantages in pricing power and market share can be secured before rival therapies enter the market. The uncertainty inherent in long development horizons makes scenario analysis and timeline sensitivity testing an essential component

of valuation discipline. Adopting realistic development pacing is necessary to ensure that projected financial outcomes remain operationally viable.

4.3 R&D Spend, Milestone Payments, and Royalty Flows

Biotechnology cash flows are highly dynamic due to sustained R&D expenditure and collaboration-based financial structures. Internal development across discovery, trials, manufacturing scale-up, and regulatory submission requires long-term investment that generates no near-term revenue. Strategic partnerships can distribute this burden, with partners providing upfront payments, development milestones, and downstream royalties, thereby redistributing risk and reward. Valuation models must therefore capture the timing of cash flows in granular detail, incorporating probability-weighted milestone achievement and royalty rates tied to future sales. These partnership economics frequently serve as market tests of asset potential, informing internal forecasts. However, deal structures vary considerably, introducing modeling challenges and dependence on negotiation-specific terms. Scenario analysis must account for alternative commercialization paths, including independent launches and out-licensing arrangements. Accurately representing R&D expenditure intensity and contractual cash flows is essential to credible enterprise valuation.

4.4 Cost of Capital and Terminal Value Estimation


The cost of capital is the primary mechanism for converting uncertainty into present value, reflecting the risk that investors associate with biotech's unpredictable future cash flows. Clinical risk, financing uncertainty, limited diversification, and binary late-stage outcomes typically result in elevated discount rates for early-stage companies, which diminish as development de-risks. The choice of discount structure, whether constant, phase-adjusted, or probability-based, is therefore an important valuation consideration. Terminal value estimation presents another significant challenge, as it captures long-term cash generation beyond the explicit forecast period. Strategic assumptions regarding market exclusivity, competitive erosion, pricing sustainability, and lifecycle management play a critical role in defining terminal outcomes. Because terminal value can represent a substantial share of total valuation, overly optimistic growth or margin assumptions can significantly bias results. Rigorous sensitivity analysis, benchmarking against comparable assets, and alignment with industry lifecycle evidence are therefore necessary to maintain analytical plausibility in biotech financial modeling.

V. QUANTIFYING UNCERTAINTY IN EARLY-STAGE BIOTECH

The high levels of scientific, regulatory, and commercial uncertainty inherent in early-stage biotechnology valuation render deterministic forecasting insufficient for constructing a credible financial model. At the discovery and preclinical stage, empirical data to validate probability estimates, development schedules, and future market performance is extremely limited. As a result, valuation increasingly relies on stochastic modeling, systematic scenario construction, and empirical benchmarking to transform uncertainty into analytically tractable form [20]. These probabilistic methods do not eliminate uncertainty, but they provide probability distributions, downside exposure profiles, and decision ranges that more realistically reflect innovation risk. Monte Carlo simulation allows many parameters to be varied simultaneously, while sensitivity analysis isolates the assumptions that exert the greatest influence on valuation [21]. These tools are supplemented by scenario planning, which maps discrete strategic futures, such as an expedited approval, a licensing partnership, or a clinical setback, each with its own distinct financial trajectory. Model assumptions are further grounded in

observable industry evidence drawn from historical clinical outcomes and comparable transactions. Together, these techniques shift biotech valuation from single-point estimation to probabilistic decision science, improving transparency, investor interpretation, and capital allocation discipline in environments where information is not fixed, but evolves [22].

Figure 2. Framework for Quantifying Uncertainty in Early-Stage Biotech Valuation



5.1 Monte Carlo Simulations and Sensitivity Analysis

Monte Carlo simulation is among the most powerful tools for modeling multivariate uncertainty in biotech valuation. Rather than applying fixed assumptions, the method assigns probability distributions to critical variables, such as clinical success rates, development duration, peak market share, pricing, and cost of capital, and simulates thousands of valuation outcomes. The resulting distribution provides insight into expected value, variance, and tail risk, enabling analysts to quantify downside exposure and upside potential. Sensitivity analysis complements this technique by systematically varying individual parameters to determine which assumptions exert the greatest influence on valuation. In early-stage biotech, model sensitivity is most commonly driven by the probability of technical success, launch timing, and terminal market penetration. Identifying these key drivers focuses due diligence efforts, improves transparency around assumptions, and sharpens investment decision-making. Together, simulation and sensitivity methods translate qualitative uncertainty into quantifiable financial risk.

5.2 Scenario Planning and Risk Weighting

Scenario planning adds a structured narrative dimension to uncertainty quantification by modeling discrete future states rather than continuous probability distributions. Common biotech valuation scenarios include clinical success followed by independent commercialization, success followed by licensing or acquisition, approval delay with reduced market share, and complete clinical failure. Each pathway carries its own assumptions regarding timing, capital requirements, competitive dynamics, and revenues. Probability-weighting these scenarios produces expected valuation ranges that reflect strategic reality rather than mere statistical abstraction. Scenario analysis is particularly valuable when empirical probability data is limited, or when managerial choices, such as the selection of partners or trial redesign, have a substantial effect on outcomes. By explicitly connecting strategic decisions to financial implications, scenario

planning enhances the decision-making utility of valuation models and improves communication among scientific, financial, and investment stakeholders.

5.3 External Benchmarking and Historical Success Rates

External benchmarking grounds early-stage valuation assumptions in observed industry evidence, reducing reliance on subjective judgment. Historical clinical transition probabilities, development timelines, licensing economics, and acquisition multiples can all be used to calibrate probability-weighted cash flow models. Benchmarking across therapeutic areas is especially important given that success rates, regulatory pathways, and commercialization opportunities vary significantly by indication and modality. Assumptions regarding royalty structures, milestone payments, and peak sales expectations are similarly informed by comparable-company analysis and precedent transactions. While historical data cannot predict the outcomes of genuinely novel innovations, particularly those involving new mechanisms or platform technologies, it provides a reality check that improves model robustness and reinforces investor confidence. Combining benchmarking with probabilistic simulation and scenario analysis creates a triangulated valuation framework capable of anchoring uncertainty in evidence rather than assumption alone, ultimately supporting more informed early-stage biotech decision-making.

VI. MARKET-BASED INDICATORS OF INTANGIBLE VALUE

Because biotechnology businesses derive a substantial share of their economic value from codified scientific knowledge, enforceable intellectual property, and uncertain developmental paths, empirically observable market transactions often provide the most reliable proxies for intangible value. Unlike internally constructed valuation models, whose outputs depend heavily on probabilistic assumptions, parameter selection, and scenario construction, market-based indicators reflect actual capital allocation decisions made under conditions of competitive due diligence and information asymmetry. Licensing structures, merger and acquisition (M&A) activity, and changes in analyst coverage or investor sentiment all translate qualitative measures of scientific credibility into quantitative financial signals, including upfront consideration, milestone contingencies, royalty structures, acquisition premiums, and forward valuation multiples. These mechanisms serve simultaneously as ex post validation of model-derived estimates, and as ex ante calibration benchmarks that constrain assumption selection and reduce valuation dispersion across analysts. However, transaction prices must be interpreted within their broader strategic and macrofinancial context, since observed valuations may incorporate synergistic portfolio effects, negotiation dynamics, or cyclical capital market conditions that do not reflect standalone intrinsic value. Accordingly, rigorous biotech valuation practice combines market-derived evidence with probabilistic cash flow modeling and clinical benchmarking into a triangulated, decision-relevant estimate of enterprise value that better reflects the economic worth of intangible biomedical innovation [23]-[25].

Table 5. Market-Based Indicators of Intangible Value in Biotechnology

Indicator Category	Core Mechanism	Key Financial Signals	Valuation Insight Provided	Advantages	Limitations / Risks

Licensing Deals and Upfront/Back-End Payments	External partner obtains development or commercialization rights to a therapeutic asset or platform	Upfront payments, development and regulatory milestones, sales-based royalties, option fees	Reveals third-party assessment of scientific credibility, probability of success, and commercial potential	Real market validation; probability-weighted cash-flow benchmarks; insight into risk sharing	Deal-specific negotiation dynamics; strategic motivations of partners; limited comparability across therapeutic areas
M&A Transactions and Strategic Buyouts	Acquisition of a biotech firm or specific pipeline assets by a larger pharmaceutical or biotech company	Acquisition premium over market price, earn-outs, contingent value rights (CVRs), integration synergies	Indicates perceived long-term strategic value of pipeline, platform technology, or intellectual property	Holistic valuation signal; incorporates competitive bidding and due diligence; captures control value	Prices may reflect synergies rather than standalone value, influenced by market cycles and financing conditions
Analyst Reports and Investor Sentiment	Equity research coverage, target prices, recommendation trends, and capital market behavior	Valuation multiples, consensus price targets, rating revisions, trading volume, and funding rounds	Provides forward-looking market expectations and perception of clinical or regulatory milestones	High-frequency information captures sentiment shifts; useful for short- to medium-term valuation context	Susceptible to behavioral bias, herd effects, and information asymmetry; may diverge from fundamental value

VII. ACCOUNTING AND REGULATORY CONSIDERATIONS

Accounting standards and regulatory requirements play an essential role in shaping how intangible assets, development expenses, and risk exposures are presented in biotechnology financial statements, and consequently, how valuation models interpret firm value. The operating characteristics of most biotech enterprises, typically pre-revenue and research-intensive, tend to produce a substantial disconnect between reported book value and economic potential [26]. Regulatory reporting standards are designed to promote transparency, comparability, and investor protection, but they introduce recognition thresholds that limit the measurement of future economic benefits

and obscure the financial expression of scientific progress [27]. Variations across jurisdictions, evolving disclosure requirements, and growing analyst and investor demands for fair value estimation add further complexity to interpretation [28]. This has created a need not only for financial modeling capability, but also for a nuanced understanding of accounting classification, disclosure regimes, and regulatory risk communication in order to effectively value biotech firms [29]. Integrating these considerations into valuation practice can enable a more precise reconciliation between financial statement reporting and probabilistic valuation outputs, enhancing decision-making usefulness and reducing information asymmetry in life-science capital markets [30].

7.1 GAAP vs. IFRS Treatment of Intangibles

The treatment of intangible assets under Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS) produces material differences in biotechnology financial reporting and valuation interpretation. Under GAAP, most internally generated research and development costs are expensed as incurred, which prevents the capitalization of early-stage innovation and therefore reduces reported asset bases during development phases. By contrast, IFRS permits conditional capitalization of development costs where technical feasibility, commercial intent, and probable economic benefit can be demonstrated. This divergence can produce significant cross-jurisdictional variation in balance sheet reporting, earnings volatility, and reported returns for otherwise comparable biotech companies. For valuation practitioners, it is therefore necessary to reconcile GAAP- and IFRS-based financials to ensure consistent estimation of invested capital, profitability cycles, and intangible value creation across global markets.

7.2 Reporting Standards and Fair Value Challenges

Fair value measurement adds further complexity to biotechnology valuation, as liquid markets for early-stage scientific assets do not exist, requiring heavy reliance on model-based estimation. Valuation inputs are frequently classified within Level 3 fair value hierarchies, where the key inputs, such as the probability of clinical success, discount rates, and estimated peak sales, are largely unobservable. Although disclosure requirements are intended to improve transparency around these assumptions, significant subjectivity remains, which can produce variability across firms and reporting periods. In addition, rapidly evolving clinical data or regulatory feedback can trigger material remeasurement events, amplifying earnings volatility and complicating investor interpretation. Sound governance, sensitivity disclosure, and methodological consistency are therefore essential to maintaining credibility in fair value reporting within the biotech industry.

7.3 Sector-Specific Risk Disclosures

Biotechnology companies face distinct regulatory, scientific, and commercialization risks that require sector-specific disclosures beyond standard financial reporting. These include clinical trial failures, regulatory rejection or delays, manufacturing scale-up challenges, pricing and reimbursement uncertainty, intellectual property litigation, and dependence on external financing. Adequate disclosure of these risks gives investors the basis to assess probability-adjusted impacts and downside exposure, supporting more informed capital allocation decisions. However, disclosure practices remain inconsistent in scope and specificity, and forward-looking statements are often constrained by legal liability considerations. Greater consistency, specificity, and alignment between risk narratives and underlying financial models would improve the correlation between

regulatory reporting and valuation frameworks, ultimately contributing to more efficient markets within the biotechnology investing ecosystem.

VIII. EMERGING TECHNOLOGIES IN VALUATION MODELLING

The rapid growth of data science, artificial intelligence (AI), and digital health analytics is transforming how uncertainty, clinical probability, and market dynamics are integrated into biotechnology valuation models [31]. While conventional valuation models are grounded in financial theory, they typically rely on fixed assumptions and limited historical data, constraining their ability to reflect evolving scientific evidence [32]. Recent advances in computation now allow vast amounts of biomedical information, real-time clinical outcomes, and unstructured data sources to be incorporated into probabilistic forecasting systems, improving precision and transparency. Machine learning algorithms can identify nonlinear relationships between trial design, biomarker response, patient heterogeneity, and regulatory outcomes, yielding more accurate estimates of development probabilities of success and timelines [33]. Simultaneously, natural language processing (NLP) can automatically extract relevant signals from clinical trial registries, regulatory filings, scientific literature, and earnings communications, substantially expanding the informational basis of valuation inputs [34]. The growing availability of real-world evidence (RWE), drawn from electronic health records, claims data, and post-marketing surveillance, further enables dynamic updating of commercial assumptions related to treatment adoption, safety profiles, and comparative effectiveness. Together, these technologies support a shift from static, assumption-based valuations to adaptive, data-augmented decision frameworks. However, methodological transparency, data governance, and model interpretability remain the most significant challenges, particularly in a healthcare context where regulatory standards demand explainability and auditability [35]. Understanding how these emerging analytical technologies are reshaping valuation practice is therefore central to developing next-generation biotech financial models that more faithfully reflect the uncertain yet information-rich environment of biomedical innovation.

8.1 Use of AI and Predictive Modelling in Clinical Outcomes

Computational analytics and artificial intelligence are increasingly applied to the prediction of clinical trial success, patient response variability, and regulatory approval outcomes, enhancing the probabilistic rigor of biotech valuation. Machine learning models trained on historical trial data can uncover nonlinear predictors of trial success, including biomarker stratification, endpoint selection, sample size, and disease-area characteristics that conventional statistical tools may fail to detect. These predictive capabilities enable more granular refinement of PTRS estimates, improving the accuracy of risk-adjusted cash flow forecasts. In addition, AI-driven simulations can dynamically update probability models as new clinical data becomes available, allowing valuation models to evolve alongside the development lifecycle rather than remaining anchored to initial assumptions. Beyond probability estimation, predictive modeling also informs time-to-market expectations, safety risk profiling, and comparative therapeutic positioning, all of which have material effects on anticipated revenue patterns. Adoption of these approaches, however, introduces concerns regarding data quality, algorithmic bias, reproducibility, and regulatory acceptance. Ensuring transparency in model validation and consistency with clinical evidence standards is a prerequisite before AI-based predictions can be reliably incorporated into investment decision-making cycles. With appropriate governance, AI-mediated forecasting has significant potential to reduce valuation uncertainty and strengthen evidence-based discipline in the valuation of early- and mid-stage biotech assets.

8.2 Natural Language Processing (NLP) for Data Extraction

NLP offers a scalable method for converting unstructured medical and financial text into structured variables that can be incorporated into valuation models. The biotechnology information ecosystem generates vast quantities of text-based content, including clinical trial protocols, regulatory submissions, scientific publications, patent applications, and corporate disclosures, that cannot be analyzed efficiently through manual review. NLP tools such as named-entity recognition, topic modeling, and sentiment analysis support the automated identification of drug mechanisms, trial endpoints, safety signals, partnership developments, and regulatory commentary, transforming qualitative narrative into quantifiable indicators. This systematic extraction enables more timely and objective updating of valuation assumptions, reflecting real-time developments in the progression of programs and shifts in market perception. Furthermore, NLP-based sentiment analysis applied to analyst reports, conference transcripts, and investor communications can detect shifts in expectations ahead of formal valuation revisions, supporting anticipatory modeling. Despite these advantages, challenges related to contextual interpretation, domain-specific terminology, multilingual datasets, and validation accuracy remain. Without proper management, mismatched or partial extraction could propagate errors into financial projections. NLP must therefore be integrated into valuation processes with rigorous curation pipelines, human oversight, and ongoing model retraining. When applied with discipline, NLP can materially enhance the informational scope and responsiveness of biotechnology valuation models.

8.3 Integrating Real-World Evidence into Assumption Sets

The incorporation of real-world evidence (RWE) represents a significant development in biotech valuation methodology, as it allows post-trial and real-world data to inform commercial and clinical assumptions. Electronic health records, insurance claims, patient registries, and pharmacovigilance databases offer insights into treatment efficacy, safety outcomes, adherence, and population heterogeneity that extend beyond the boundaries of controlled clinical settings. Incorporating these data sources into valuation models improves estimates of market penetration, therapy duration, price stability, and long-term competitive dynamics, refining both revenue projections and long-term lifecycle value. Regulatory decisions and label expansion are also influenced by RWE, and can substantially alter projected cash flows and risk profiles. However, methodological challenges, including data standardization, confounding bias, privacy governance, and evidentiary acceptance, must be carefully managed to preserve analytical reliability. When linked to probabilistic valuation structures, RWE enables assumptions to be continuously updated as real-world performance is observed, transforming valuation into a learning system. This adaptive functionality is increasingly important in precision medicine and specialized therapeutic areas where clinical continuity and integration with the healthcare system are central to long-term intervention value.

IX. CHALLENGES AND FUTURE DIRECTIONS

Despite significant methodological progress in biotechnology valuation, persistent structural challenges continue to constrain comparability, transparency, and predictive reliability across models and market participants [36]. Chief among these is the extreme sensitivity of valuation outputs to underlying assumptions, particularly the probability of clinical success, development timelines, pricing, and discount rates [37]. Because these parameters frequently depend on incomplete scientific observations and expert assessment, materially different enterprise values can emerge from similar data sets across analysts. Furthermore, rapidly evolving regulatory environments, accelerating scientific innovation, and shifting capital market conditions introduce time-varying

uncertainty that traditional valuation techniques are ill-equipped to address [38]. The growing integration of artificial intelligence, real-world evidence, and advanced simulation methods presents meaningful opportunities to improve accuracy and adaptive learning in valuation systems, yet these same methods introduce novel governance, explainability, and data quality challenges that require careful management [39]. Looking ahead, biotech valuation is expected to evolve toward greater reliance on standardized assumption frameworks, improved disclosure practices, and hybrid analytical approaches that integrate quantitative rigor with domain expertise. Advancing these priorities could enhance investor confidence, reduce information asymmetry, and improve the efficiency of capital allocation toward scientifically and clinically valuable innovation. Identifying viable paths to methodological alignment and engaging the relevant stakeholders remains a key interface between academic research and business practice in life-science finance [40].

9.1 Standardizing Assumptions Across the Sector

The absence of industry-wide conventions on key modeling assumptions, including technical probabilities of success, development timelines, cost structures, and commercialization parameters, is among the most significant impediments to consistent biotech valuation. Although industry benchmarks and historical data exist, their application varies widely across analysts, therapeutic areas, and geographies, producing a broad dispersion in valuation outputs. The establishment of reference ranges, potentially facilitated by industry organizations, regulatory bodies, or market data-sharing alliances, could materially improve comparability and analytical plausibility. Standardization does not imply uniformity; rather, it provides a clear baseline against which to evaluate reasonable deviations. Such harmonization would facilitate benchmarking across companies, improve model transparency, and support more efficient decision-making in biotechnology capital markets.

9.2 Improving Transparency and Communication with Stakeholders

Open reporting on valuation assumptions, methodologies, and uncertainty ranges is essential for building trust among investors, regulators, and strategic partners. Historically, biotech valuation models have often been treated as proprietary analytical tools, limiting external scrutiny and perpetuating information asymmetry. Disclosing probability inputs, scenario structures, sensitivity analyses, and data sources would enhance interpretability and enable more informed stakeholder engagement. Greater transparency will be particularly important as AI-based and data-intensive valuation approaches gain traction, since complex models can obscure the underlying logic. Clear narrative explanations, standardized reporting formats, and alignment between financial estimates and clinical data can all contribute to improved credibility and accountability. Enhanced communication ultimately supports more stable capital formation and sustains long-term investor confidence in innovation-driven enterprises.

9.3 Hybrid Approaches: Blending Quantitative Models with Expert Judgement

The future of biotechnology valuation lies in hybrid analytical systems that combine quantitative modeling with structured expert judgment. Purely statistical or simulation-based approaches may overlook nuanced scientific considerations, while intuition-based judgment alone can be inconsistent and subject to bias. More balanced and decision-relevant valuation outputs can be achieved through financial models that integrate probabilistic financial modeling, AI-assisted forecasting, and multidisciplinary expert analysis. Formal mechanisms such as expert elicitation, Bayesian updating, and governance committees can be used to structure qualitative knowledge within

quantitative frameworks. These hybrid approaches acknowledge that biotech valuation is most effectively conducted at the intersection of science, regulation, and finance, a domain where uncertainty cannot be eliminated, but can be better interpreted. Developing robust and flexible hybrid systems therefore constitutes a critical direction for enhancing the power and utility of next-generation valuation frameworks.

CONCLUSION

This paper has addressed the central challenge of valuing biotechnology companies, whose economic value is largely non-cash in nature, rooted in intangible scientific resources, probabilistic development trajectories, and evolving regulatory and market conditions, rather than stable historical cash flows. Through this analysis, the paper demonstrated that valuation outcomes are heavily shaped by operating model assumptions, including the probabilities of technical and regulatory success, development progression, capital intensity, partnership economics, and discount rate selection. The traditional financial models used in this domain, discounted cash flow, risk-adjusted net present value, and real options analysis, are all foundational, but their performance depends on the rigor, transparency, and empirical grounding of the assumptions they embody. The review also highlighted how uncertainty quantification techniques, market transaction indicators, accounting and disclosure frameworks, and emerging technology-enabled data sources collectively influence the credibility of early- and mid-stage biotech valuation estimates.

Among the key findings is that no single methodological approach can fully capture the multidimensional uncertainty and intangible value creation inherent in biomedical innovation. Effective valuation instead relies on triangulation, combining probabilistic modeling, empirical benchmarking, strategic market evidence, and applied scientific judgment. The convergence of artificial intelligence, natural language processing, and real-world evidence with valuation practice offers promising opportunities to improve predictive accuracy and adaptive learning; however, these advances must be accompanied by sound governance, explainability standards, and consistent disclosure to preserve investor trust. The path forward for biotech valuation likely lies in harmonizing assumptions across the sector, improving transparency, and developing hybrid analytical models capable of bridging the gap between quantitative finance and domain expertise. These priorities will better position stakeholders to align capital allocation with scientifically viable innovation, ultimately enabling more effective investment decisions, the development of superior therapies, and sustainable value creation across the life sciences ecosystem.

REFERENCES

1. Nelson, T. R., & Mukherji, A. (1998). Valuing biotechnology assets. *Nature biotechnology*, 16(6), 525–529.
2. Segnani, M., & Ferrari, E. (2018). The determinants of venture capital pre-money valuation: the case of European biotechnology startups.
3. Copeland, T. (2001). *Real Options: A Practitioner's Guide*. Texere LLC.
4. Pisano, G. P. (2006). *Science business: The promise, the reality, and the future of biotech*. Harvard Business Press.
5. Lev, B. (2000). *Intangibles: Management, measurement, and reporting*. Bloomsbury Publishing USA.
6. Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. *Nature reviews Drug discovery*, 8(12), 959–968.

7. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: new estimates of R&D costs. *Journal of health economics*, 47, 20–33.
8. Cockburn, I. M., & Henderson, R. M. (2001). Scale and scope in drug development: unpacking the advantages of size in pharmaceutical research. *Journal of health economics*, 20(6), 1033–1057.
9. Koller, T., Goedhart, M., & Wessels, D. (2010). *Valuation: measuring and managing the value of companies*. John Wiley & Sons.
10. Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010). How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nature reviews Drug discovery*, 9(3), 203–214.
11. Hall, B. H., & Lerner, J. (2010). The financing of R&D and innovation. In *Handbook of the Economics of Innovation* (Vol. 1, pp. 609–639). North-Holland.
12. Woo, J., Kim, E., Sung, T. E., Lee, J., Shin, K., & Lee, J. (2019). Developing an improved risk-adjusted net present value technology valuation model for the biopharmaceutical industry. *Journal of Open Innovation: Technology, Market, and Complexity*, 5(3), 45.
13. Arora, A., Fosfuri, A., & Gambardella, A. (2004). *Markets for technology: The economics of innovation and corporate strategy*. MIT Press.
14. Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. *Administrative science quarterly*, 35(1), 128–152.
15. Ernst, Y., & Young, T. (2006). *Beyond borders: Global biotechnology report 2006. Back on Track – The European Perspective*.
16. Dixit, A. K. (1994). *Investment under uncertainty*. Princeton University Press.
17. Fogel, D. B. (2018). Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. *Contemporary clinical trials communications*, 11, 156–164.
18. De Backer, R., Ruby, T., & Saxena, A. (2017). *Biopharma Valuations, Onward and upward*.
19. Deloitte, L. (2013). *Measuring the return from pharmaceutical innovation 2013. Weathering the storm*, 1–35.
20. Glasserman, P. (2004). *Monte Carlo methods in financial engineering* (Vol. 53). New York: Springer.
21. Hull, J. C., & Basu, S. (2016). *Options, futures, and other derivatives*. Pearson Education India.
22. Beynon, K., & Porter, A. (2000). *Valuing pharmaceutical companies: A guide to the assessment and evaluation of assets, performance and prospects*. Woodhead Publishing.
23. Rydzewski, R. M. (2010). *Real world drug discovery: A chemist's guide to biotech and pharmaceutical research*. Elsevier.
24. Bergeron, B., & Chan, P. (2004). *Biotech industry: A global, economic, and financing overview*. John Wiley & Sons.
25. Araja, D. (2023). Insights into trends and challenges of the pharmaceutical industry: the role of scientific business research. *Journal of Business Management*, 21, 48–63.
26. An, I. M. A. P. (2011). *Pharmaceuticals & Biotech Industry Global Report—2011*.
27. Dharmamoorthy, G., Sabareesh, M., Balaji, A., Dharaniprasad, P., & Swetha, T. (2022). An overview on top 10 pharma industry trends and innovations 2022. *YMER Journal*, 21(11), 2123–2140.
28. Yuyan, G. (2023). A financial analysis report of three typical biopharmaceutical companies in UK. *Academic Journal of Business & Management*, 5(1), 165–170.
29. Heinonen, M. (2002). Disclosure of the dealings between drug developing companies and the FDA under the federal securities laws.

30. Fisher, W. O. (2001). Key disclosure issues for life sciences companies: FDA product approval, clinical test results, and government inspections. *Mich. Telecomm. & Tech. L. Rev.*, 8, 115.
31. Topol, E. (2019). *Deep medicine: how artificial intelligence can make healthcare human again*. Hachette UK.
32. Nyiramana Mukamurera, P. (2024). The role of artificial intelligence in clinical decision support systems. *Research Invention Journal of Public Health and Pharmacy*, 3(2), 14–17.
33. Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. *Nature medicine*, 25(1), 24–29.
34. Kreimeyer, K., Foster, M., Pandey, A., et al. (2017). Natural language processing systems for capturing and standardizing unstructured clinical information: a systematic review. *Journal of biomedical informatics*, 73, 14–29.
35. U.S. Food and Drug Administration (FDA). Framework for FDA's real-world evidence program. 2018.
36. Galindo-Rueda, F. (2013). The OECD measurement agenda for innovation. In *Handbook of innovation indicators and measurement* (pp. 217–246). Edward Elgar Publishing.
37. DiMasi, J. A., & Grabowski, H. G. (2007). The cost of biopharmaceutical R&D: is biotech different? *Managerial and Decision Economics*, 28(4–5), 469–479.
38. Nicotera, G., Sferrazza, G., Serafino, A., & Pierimarchi, P. (2019). The iterative development of medicines through the European Medicine Agency's adaptive pathway approach. *Frontiers in Medicine*, 6, 148.
39. Francisco, M., & Linnér, B. O. (2023). AI and the governance of sustainable development. An idea analysis of the European Union, the United Nations, and the World Economic Forum. *Environmental Science & Policy*, 150, 103590.
40. Lazonick, W., & Tulum, Ö. (2011). US biopharmaceutical finance and the sustainability of the biotech business model. *Research Policy*, 40(9), 1170–1187.